Sydney-based regulatory affairs expert Arthur Brandwood discussed the recent changes made by the Australian Therapeutic Goods Administration (TGA).

Arthur also covered:
• Australia’s aggressive deregulatory agenda
• The Australian tax incentive (43.5% for R&D expenditure)
• The simple process for regulation of clinical trials in Australia
• TGA’s web based submission process for device approvals

So if you or members of your team do medical device business in Australia, watch the replay, download the slides, and read the transcript.